This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
ACTBL2 Polyclonal Antibody
catalog :
PA5-102030
quantity :
100 uL
price :
US 464.00
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human, mouse
application :
western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section
product information
Product Type :
Antibody
Product Name :
ACTBL2 Polyclonal Antibody
Catalog # :
PA5-102030
Quantity :
100 uL
Price :
US 464.00
Clonality :
Polyclonal
Purity :
Affinity chromatography
Host :
Rabbit
Reactivity :
Human, Mouse
Applications :
Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:50-1:200, Western Blot: 1:500-1:1,000
Species :
Human, Mouse
Isotype :
IgG
Storage :
-20 C
Description :
Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.
Immunogen :
A synthesized peptide derived from human ACTBL2(Accession Q562R1), corresponding to amino acid residues H89-A139.
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:50-1:200, Western Blot: 1:500-1:1,000
Aliases :
4732495G21Rik; ACT; Actbl2; actin, beta like 2; actin, beta-like 2; actin-like protein; beta-actin-like protein 2; Kappa-actin
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments